

Image copyright Dennis Kunkel Microscopy, Inc.

14TH

SPORE

INVESTIGATORS' WORKSHOP

INFORMATION BROCHURE

BALTIMORE MARRIOTT WATERFRONT

JULY 16–19, 2006

PARTICIPANTS

Message to Participants

The 14th SPORE Investigators' Workshop is an open meeting to SPORE investigators, patient advocates, and industry representatives.

The presentations shown during the session are the explicit property of the speaker and are not to be duplicated without written consent from the primary author(s). Presentations should not be considered confidential.

The agenda is subject to change. For the latest information, please visit our Web site: <http://sporemeeting.nci.nih.gov>.

INDUSTRY

Special Message to Industry

Commercial product promotion or exhibits are not permitted. The Workshop goal is to promote direct interaction with SPORE researchers interested in discussing collaborative research activities that are complementary with industry objectives.

CONTENTS

14TH SPORE

Investigators' Workshop

Contents

Messages to Participants and Industry

Welcome Letters 1

- Dr. Andrew von Eschenbach 1
Director, National Cancer Institute
- Dr. Jorge Gomez 2
Chief, Organ Systems Branch, National Cancer Institute

Agenda at a Glance 3

Extended Agenda 4

Workshop and Session Objectives 6

Satellite and Industry Opportunities 10

Abstract Submission Guidelines 11

Internet Access and Speaker Ready Rooms 12

Poster Guidelines 13


Presentation Submission Guidelines 13

General Information 14

- Workshop Deadlines 14
- Workshop Registration Information 14
- Hotel Information 15
- Airport and Ground Transportation Information 16

Meeting Support and Special Acknowledgements 17

Contact Information 19



LETTER

Letter From Dr. Andrew von Eschenbach,
Director, National Cancer Institute

Since the passage of the National Cancer Act in 1971, the growth in knowledge of the molecular machinery of the cell has exploded. In 1995 with the completion of the human genome sequence, scientists achieved an historic milestone in the pursuit of understanding the fundamental nature of life. The National Cancer Institute (NCI) has been driving the proliferation of more research data relevant to the understanding of disease, and oncology is now leading biomedical research into the era of molecular medicine.



The certainty of this new era is that the trajectory will be entirely different from that in the past. Molecular oncology is not merely an extrapolation of the knowledge gained from the macroscopic and microscopic views of cancer, but defines an entirely new state of knowledge. The changes in our understanding call for a new solution strategy characterized by a “systems” or integrated biology approach. The future of cancer research hinges on interdisciplinary cross-cutting science. The program for the 14th SPORE Investigator’s Workshop contains many of the innovative approaches that will move us toward a broad portfolio of opportunity that will allow researchers to predict and prevent the onset or evolution of the process, to detect and eliminate cancer earlier and more simply, and to control the rate and method of progression of the disease process.

In addition to creating an extraordinary infrastructure of intellectual and physical resources, including the Cancer Centers and SPORE programs, the National Cancer Program serves as the optimal platform for an interactive network that embraces the challenge of collaborations within the NIH, with other Federal agencies, and with the for-profit sector. The SPORE Workshop has grown tremendously in the past years and is a testimony to the NCI’s ability to engage a broad community in a national collaboration against cancer.

Andrew C. von Eschenbach, M.D.

LETTER

Letter From Dr. Jorge Gomez, Chief, Organ Systems Branch, National Cancer Institute

The Organ Systems Branch (OSB) at the National Cancer Institute (NCI) continues to break boundaries and expand our borders in science and research. True to our mission, we are preparing to further enhance the interchange of ideas and scientific interactions among the SPORE investigators, collaborators, NCI networks, and industry partners.



Just a few years ago, we asked the question “What are the barriers to translational research?” Since then we have worked diligently to make greater strides and move discoveries toward human application and further our knowledge for better cancer patient management.

In pursuing our mission, many bridges were made—scientists, clinicians, biostatisticians, basic and applied researchers, administrators, and patient advocates. These simple structures allowed communication to flow in both directions and helped to develop well-forged partnerships. Let me say that the patient advocate interactions with researchers have made vast improvements to facilitate translational research—in outreach and educational programs affecting clinical trial accruals and IRB approvals.

Even under Federal budgetary constraints, the OSB seeks to improve ways to maximize available resources and tools for our investigators. The idea of forming partnerships with nonprofit and for-profit organizations has benefited not only the SPOREs but also other NCI programs and networks.

In this year’s Workshop, we propose to reconfirm our goals—SPORE program integration with a clear focus to advance discoveries, create much-needed networks within the NCI, and enhance interactions with nonprofit and for-profit organizations, including industry partners.

We work best when we can work together.

I welcome all of you to the 14th SPORE Investigators’ Workshop in July 2006.

See you in Baltimore!

Jorge Gomez

AGENDA

Agenda at a Glance

	Sunday 07/16/06				Monday 07/17/06			Tuesday 07/18/06		Wednesday 07/19/06	
	<div>National Biospecimen Network Meeting</div> <div><div>Lung Cancer Proteomics Meeting</div><div>Administrators’ Meeting</div><div>Patient Advocates’ Session</div></div>				Registration 7:00 a.m. - 7:00 p.m.		Registration 7:00 a.m. - 7:00 p.m.		Registration 7:00 a.m. - 12 noon		
7:00 a.m.					Breakfast		Breakfast		Breakfast		
7:30 a.m.					<div>Organ Site Breakout Sessions I: GU, Breast, Lung, GI/Pancreas, Skin</div> <div>Poster Viewing</div>		IP Management: Technology Transfer	DHHS Cross-cutting Initiatives I	Concurrent Plenary Sessions		
8:00 a.m.											
8:30 a.m.											
9:00 a.m.											
9:30 a.m.											
10:00 a.m.							Mini-symposia		Organ Site Breakout Wrap-up Sessions		
10:30 a.m.											
11:00 a.m.											
11:30 a.m.					<div>SPORE Directors’ & Patient Advocates’ Working Luncheon</div> <div>Lunch on Your Own</div>		Patient Advocates’ Wrap-up Session				
12 noon											
12:30 p.m.											
1:00 p.m.	<div>Plenary Session</div>				<div>Organ Site Breakout Sessions II: Prostate, Hematological Malignancies, Head & Neck, Brain, Ovarian/GYN</div> <div>Poster Viewing</div>		Working Groups				
1:30 p.m.											
2:00 p.m.											
2:30 p.m.											
3:00 p.m.											
3:30 p.m.											
4:00 p.m.	<div>Meet the Author Poster Session and Dinner Buffet</div>		<div>FDA Regulatory Issues</div> <div>DHHS Cross-cutting Initiatives II</div>		Satellite Meetings						
4:30 p.m.											
5:00 p.m.											
5:30 p.m.											
6:00 p.m.	<div>Welcome Reception</div>	<div>Poster Setup</div>									
6:30 p.m.											
7:00 p.m.											
7:30 p.m.											
8:00 p.m.											
8:30 p.m.											

AGENDA

Extended Agenda

Sunday, July 16

10:00 a.m. - 3:00 p.m.	National Biospecimen Network Meeting
1:00 p.m. - 2:45 p.m.	Lung Cancer Proteomics Meeting
	Administrators' Meeting
	Patient Advocates' Session
2:45 p.m. - 3:00 p.m.	Break
3:00 p.m. - 6:00 p.m.	Plenary Session
6:00 p.m. - 9:00 p.m.	Welcome Reception
	Poster Setup

Monday, July 17

7:00 a.m. - 7:00 p.m.	Registration
7:00 a.m. - 8:00 a.m.	Breakfast
8:00 a.m. - 12 noon	Organ Site Breakout Sessions I
	<ul style="list-style-type: none"> • GU • Breast • Lung • GI/Pancreas • Skin
	Poster Viewing
10:00 a.m. - 10:15 a.m.	Break
12 noon - 2:00 p.m.	Executive Luncheon (by invitation)
	Patient Advocates' Luncheon (by invitation)
	Lunch on Your Own
2:00 p.m. - 6:00 p.m.	Organ Site Breakout Sessions II
	<ul style="list-style-type: none"> • Prostate • Hematological Malignancies • Head and Neck • Brain • Ovarian/GYN
	Poster Viewing

AGENDA

Extended Agenda

4:00 p.m. - 4:15 p.m.	Break
6:00 p.m. - 9:00 p.m.	Meet the Author Poster Session and Dinner Buffet

Tuesday, July 18

7:00 a.m. - 7:00 p.m.	Registration
7:00 a.m. - 8:00 a.m.	Breakfast
8:00 a.m. - 9:45 a.m.	IP Management: Technology Transfer DHHS Cross-cutting Initiatives I
9:45 a.m. - 10:00 a.m.	Break
10:00 a.m. - 12 noon	Mini-symposia
12 noon - 2:00 p.m.	SPORE Directors' and Patient Advocates' Working Luncheon (by invitation) Lunch on Your Own
2:00 p.m. - 5:00 p.m.	Working Groups
5:00 p.m. - 5:15 p.m.	Break
5:15 p.m. - 7:00 p.m.	FDA Regulatory Issues DHHS Cross-cutting Initiatives II
7:00 p.m. - 9:00 p.m.	Satellite Meetings

Wednesday, July 19

7:00 a.m. - 12 noon	Registration
7:00 a.m. - 8:00 a.m.	Breakfast
8:00 a.m. - 10:00 a.m.	Concurrent Plenary Sessions
10:00 a.m. - 10:15 a.m.	Break
10:15 a.m. - 12 noon	Concurrent Sessions: Organ Site Breakout Wrap-up Sessions
12 noon	Workshop Adjournment
12 noon - 2:00 p.m.	Patient Advocates' Wrap-up Session

OBJECTIVES

Workshop and Session Objectives

Goals of the Workshop

The primary goal of the Workshop is to advance translational cancer research by expanding collaborations between SPORE investigators, NCI networks, industry, special guests, patient advocates, and NCI and NIH staff. The SPORE Workshop is the culmination of efforts of both basic and applied research scientists to share data, assess research strategies, identify new research opportunities, and establish priorities for research that are most likely to reduce cancer incidence and mortality and to increase survival.

Plenary Session

This is the opening meeting forum designed for NCI leadership and SPORE investigators to share new information, highlights, and opportunities. All participants can view opportunities and collaborations to promote SPORE research and discuss strategies to overcome barriers to translational research. At this first opening session of the Workshop, recognition will be given to recipients of the SPORE Outstanding Leadership Award and SPORE Outstanding Investigator Award. At the end of this session, the keynote speaker will incentivize all participants for the following 3 days.

Mini-symposia

These sessions will allow investigators to present and elicit discussions on new findings, methodologies, agents, and mechanisms that may alleviate the incidence and mortality of human cancer.

Cancer and Inflammation

Co-Chairs: Steven Dubinett, Angelo De Marzo, Jonathan Serody

Chronic inflammation has long been suggested to constitute a risk factor for a variety of malignancies. An inflammatory process is typically accompanied by generation of free radicals, overproduction of cytokines and/or chemokines, and growth and angiogenic factors. Free radicals-mediated DNA damage contributes to tumor initiation. Cytokines and growth factors can further promote tumor growth by stimulating cell proliferation, adhesion, and vascularization. Recent data have expanded the concept of inflammation as a critical component in carcinogenesis, suggesting new anti-inflammatory therapies for a complementary approach in treating a variety of tumor types.

Small Molecules in Cancer Therapy

Co-Chairs: Paolo Paoletti, Kenneth Anderson

Development of small molecules aimed against molecular targets in cancer cells represents one of the fastest growing fields in cancer treatment and prevention. Fostered by the recent success stories in the therapy of chronic myeloid leukemia, myeloma, and lung and colon cancer, to name a

OBJECTIVES

Workshop and Session Objectives

few, small molecules promise considerable potential in efficacy with minimal adverse effects. The objective of the session is to provide SPORE investigators with a forum to discuss new breakthroughs, exchange experiences, and solve problems in this highly dynamic field.

Tumor Stem Cells and Lineage Dependencies

Co-Chair: Max Wicha, TBD

Recent discoveries in a number of organ sites have brought to light the heterogeneous nature of most malignancies and sparked interest in identifying those cells crucial to the survival of the cancer. This session will highlight recent discoveries of tumor stem cells and lineage-specific survival genes and discuss their potential relevance in the development of better cancer diagnostics and therapeutics.

Steroid Hormone Receptors

Co-Chairs: Jill Siegfried, Donald Tindall

Hormone therapy is used extensively in a variety of cancers. For prostate and breast cancer, steroid hormones and their receptors are involved in initiation, progression, and prognosis of diseases. Steroid hormone receptors and related molecules are used as important targets for anticancer therapy (especially in the treatment of breast and prostate cancers). In addition to steroid hormone receptors, steroid hormone co-regulators (accessory proteins) are also involved in cancer promotion and progression. Advances in this field of research will provide opportunity for novel targeted therapies in cancer. The focus of this session will be on the role of steroid hormone receptors as targets in cancer prevention and therapy. To foster new ideas and collaborations, the session will also include discussions on mechanistic approaches including modifiers of hormone actions and steroid hormone receptors, new concepts of endocrine resistance, communication between growth factors and steroid hormone receptor pathways, and other topics. This interactive session will help bring together experts across organ sites in these scientific fields to discuss mechanistic concepts and clinical relevance, and how to further advance studies of steroid hormone receptors for the management of cancer.

Oxidative Stress

Co-Chairs: Theodore Deweese, William Nelson

There is strong evidence that oxidative stress generated both intracellularly and extracellularly is associated with carcinogenesis and cancer progression. Reactive oxygen species (ROS) and oxidative damage biomolecules are a major focus of recent etiologic cancer research. ROS cause oxidative damage to important biomolecules, such as lipids, proteins, and DNA. Oxidative modification of DNA bases leads to mutation and altered gene function resulting in carcinogenesis. ROS can also induce the expression of a variety of transcriptional factors involved in neoplastic

OBJECTIVES

Workshop and Session Objectives

transformation. Recent evidence shows that germline polymorphisms in genes related to oxygen metabolism and antioxidant activity are implicated in cancer susceptibility and that the diminution of antioxidant capacity of cells correlates with carcinogenic progression. Studies of antioxidants show preventive efficacy and pro-oxidants are also implicated in the mechanism of action of therapeutic regimens. The goal of the session is to examine the current findings relating oxidative stress to cancer etiology and therapy and to review the state of current technology to monitor oxidative stress for translational cancer research.

Working Groups

These sessions will focus on aspects of the current state of the translational cancer research climate, initiating dialogue and action in these areas.

EGFR/HER-2/Neu Targeted Therapies

Co-Chairs: Mark Sliwkowski, Bruce Johnson, Carlos Arteaga

Targeting epidermal growth factor receptor and related molecules recently led to major breakthroughs in the management of cancer. The presence of these targets in high-prevalence diseases such as lung, breast, and colon cancers guarantees major impact across patient populations and thus attracts ample attention from the scientific community and general public. The goals of the session are to invite SPORE leaders in the field to a discussion of new developments in this area, to support collaborative efforts, and to set up new objectives.

Methods in Validation of Biomarkers

Co-Chairs: William Bigbee, David Sidransky

A growing number of cancer markers are being discovered by SPORE investigators. These biomarkers are being developed to identify individuals at risk for cancer, to detect disease earlier, to estimate prognosis, to predict response to particular agents, and to monitor response to treatment. As targeted therapies develop, tumor markers are becoming all the more important in determining whether a given agent is reaching and affecting its molecular target. While the accuracy of biomarker data is key for the conduct of meaningful correlative studies, what remains to be defined are guidelines for good laboratory practice for the translational phase biomarker assay development that will provide the most accurate data. These practices include pre-analytical considerations, including specimen preparation and annotation, and also reagent preparation and quality control. Analytical considerations include the reliability of signal, accuracy, precision, and linearity, while clinical performance assessments include sensitivity, specificity, receiver operator characteristics, and predictive value. The goal of this session is to review current biomarker analysis practices and deliberate on the development of new standards for good laboratory practice that will better ensure data accuracy in translational cancer research.

OBJECTIVES

Workshop and Session Objectives

Imaging: Correlation With Biomarkers in Translational Research and Therapy

Co-Chairs: Gary Kelloff, Juri Gelovani

The objective of this session is to discuss the use of molecular, cellular, and histologic markers in combination with imaging technologies as detection tools for early cancer detection and diagnosis as well as in the context of therapies.

Clinical Trial Design in Translational Research

Co-Chairs: Donald Berry, Robert Figlin, Herbert Lyerly, Christopher Logothetis, David Parkinson

There is a trend of increasing use of randomized Phase II designs in cancer therapy. Continued improvement in study design, conduct, analysis, and reporting is required to enhance the quality of clinical trials. The accrual rate and success rate of the trials remain low, and therefore futility stopping rules to terminate ineffective treatment arm(s) should be implemented more frequently. More innovative, flexible designs for Phase II trials are needed to facilitate the development of effective cancer treatments. This session will discuss and explore the challenges faced in designing high-quality clinical trials in cancer patients. What can we do to better predict the success of a therapeutic in a clinical trial on the basis of results from the preclinical modeling? Furthermore, each phase of the clinical trials should be redefined. Investigators from NCI's Division of Cancer Treatment and Diagnosis (DCTD) are invited to be guest panel participants.

Meet the Author Poster Session

This session will offer investigators and industry the opportunity to present and share exciting research projects in an interactive forum. Meet the Author encourages one-on-one interactions, networking, and discussions to further facilitate partnerships and collaborations.

Organ Site Breakout Sessions

These breakout sessions allow organ site programs to discuss (1) the most important recent scientific advancements, (2) opportunities and technologies that can be used to advance the field, (3) collaborations with other SPORE or NCI programs and networks, and (4) infrastructures needed to support Inter-SPORE collaborations, and to propose focused activities for upcoming fall or winter meetings.

The deadline for the organ site breakout agendas is June 3, 2006.

OBJECTIVES

Workshop and Session Objectives

Concurrent Plenary Sessions

At these sessions, each SPORE has the opportunity to highlight its most groundbreaking translational research, whether initially a discovery from the laboratory going to the clinic or a clinical observation being further investigated in a laboratory setting. These talks reflect the best efforts of each SPORE to achieve a human application or intervention.

Special Sessions

- **Intellectual Property (IP) Management: Technology Transfer.** This session will provide training for all SPORE investigators and interested individuals in IP management, technology transfer, and related topics. The session will include a panel discussion with experts in the field. Participants are encouraged to bring their personal experience and solutions to problems and questions. The goal is to educate and discuss solutions to problems that hamper successful translational research in cancer.
- **FDA Regulatory Issues.** This forum, a companion session to the IP Management session, will address regulatory issues facing translational research in a format that will encourage participation by NCI and FDA representatives in the framework of presentations and panel discussions, providing educational and problem-solving opportunities.
- **DHHS Cross-cutting Initiatives I & II.** This session will address DHHS initiatives targeting research in specific, groundbreaking areas such as nanotechnology, proteomics, genomics, imaging, biomarkers, the NIH Roadmap Initiative, FDA critical paths, and the National Biospecimen Network (NBN). DHHS staff will present the strategic plans of the initiatives alongside experts presenting scientific presentations with the objective of informing SPOREs and other participants about new research opportunities as well as possibilities for coordination with these funded research initiatives.

OPPORTUNITIES

Satellite and Industry Opportunities

For information about satellite meetings and industry opportunities at the SPORE Workshop, please contact Ruby Gerald, Capital Consulting Corporation, by phone at 866-714-2551, or by e-mail at 14thSPORE@md.capconcorp.com.

The deadline for Satellite Meeting Requests is May 30, 2006.

ABSTRACT

Abstract Submission Guidelines

Abstract submission to the Mini-symposia, Concurrent Plenary, and Poster Sessions will be open to SPORE Investigators, NCI Intramural investigators, and industry. Patient advocates may submit abstracts to the Poster Session. Please submit abstracts directly to the Workshop Registration Web site, <http://sporemeeting.nci.nih.gov>. After registering for the Workshop, select "Abstract Submission" and follow the instructions on the Web site. The deadline for submitting abstracts is **April 14, 2006**.

The deadline for abstract submission is April 14, 2006.

SPORE Investigators. SPORE programs must submit **three to five abstracts** to the Workshop. No more than one abstract may be submitted to each of the Mini-symposia and Concurrent Plenary Sessions. The Planning Committee will review abstracts submitted for the Mini-symposia and Concurrent Plenary and select those for placement within these sessions. **Those not selected will be placed into the Poster Session.** Possible abstract submission scenarios include:

Possible Abstract Submission by SPORE Investigators												
Session	Example: Options for Submitting 3 Abstracts				Example: Options for Submitting 4 Abstracts				Example: Options for Submitting 5 Abstracts			
Mini-symposia			1	1			1	1	1			1
Concurrent Plenary		1		1		1		1	1	1		
Poster Session	3	2	2	1	4	3	3	2	3	4	5	4

NCI Intramural Investigators. The NCI Intramural Program may submit a total of **10 abstracts** to the Workshop. The Workshop Planning Committee will review abstracts and deliberate on session placement.

Industry. Each industry company or organization may submit a total of **five abstracts** to the Workshop. The Workshop Planning Committee will review abstracts and deliberate on session placement.

Patient Advocates. Each SPORE may submit **one** patient advocate abstract to the Poster Session.

ABSTRACT

Abstract Submission Guidelines

Special Instructions for Abstract Preparation

Please use either WordPerfect or MSWord when submitting your abstract. An example of the abstract format is displayed on the Web site.

Step 1. The title of the abstract should be in upper and lower case bold letters; do not use all capital letters.

Step 2. List the authors' full names and their affiliations beneath the title, using upper and lower case letters.

Step 3. Underline the name of the presenting author (please see illustration below). This step is crucial.

hSRBC (11p15.5-p15.4) Frequently Undergoes Epigenetic Inactivation in Lung Cancer by Promoter Region Methylation With Resulting Loss of Protein Expression

Sabine Zöchbauer-Müller¹, Kwun M. Fong², Xie Xu³, Joseph Geradts⁴, Sonja Seidl¹, Christoph C. Zielinski¹, Michael Peyton³, Adi F. Gazdar³, John D. Minna³

¹Clinical Division of Oncology, University Hospital, Vienna, Austria; ²Prince Charles Hospital, Brisbane, Australia; ³The University of Texas Southwestern Medical Center at Dallas; ⁴Roswell Park Cancer Institute, Buffalo, New York

WORKSTATIONS

Internet Access and Speaker Ready Rooms

The National Cancer Institute (NCI) will provide PC workstations for e-mail and Internet access to all SPORE investigators and Workshop participants. There will also be stations set up for laptops. In addition, these PC workstations will have printing capabilities. The NCI will also provide IT support for troubleshooting during the Workshop. We ask that you follow these simple rules:

- Please do not bring food or drink into the Internet Access Room so that we can minimize housekeeping.
- Be considerate of others by limiting your usage to 20 minutes during high-traffic periods.
- Please report technical problems immediately to the NCI Computer Services staff.

POSTER

Poster Guidelines

Investigators and industry representatives will be notified via e-mail if their abstracts have been selected for poster presentation. The poster boards are 4' by 6' wide and outfitted for Velcro displays as well as pushpins. Poster setup will take place between 6 and 10 p.m., Sunday, July 16. Poster take-down will take place on Tuesday, July 18.

PRESENTATION

Presentation Submission Guidelines

Investigators and industry representatives will be notified via e-mail whether their abstracts have been selected for PowerPoint presentation. Please submit presentations directly to the Workshop Registration Web site, <http://sporemeeting.nci.nih.gov>. Select "Presentation Submission" and follow the instructions on the Web site. You may submit original or revised presentations until June 30, 2006. When the Web site is closed, NCI Computer Services staff will then download all presentations for the Workshop.

Special Instructions for PowerPoint Presentations

- The recommended format for all presentations is Microsoft PowerPoint for PC. If your presentation is created on the Macintosh platform, please check the formatting of your presentation after converting it to the PC platform before submitting it online. The NCI Computer Services staff will troubleshoot presentations brought to the Workshop; however, this service may be minimal because of time constraints and staff resources.
- To minimize interruptions and maintain the time schedule for the Workshop sessions, we discourage the use of personal laptops. All presentations will be preloaded on a designated laptop for each session and will be set up 30 minutes before each session.
- We recommend that a backup copy of each presentation be brought to the Workshop. The following backup media types are recommended: Zip Disk, Floppy Disk, or USB Flash Drive. CDs are permissible, but there is a potential for formatting issues, and we therefore highly recommend the use of USB Flash Drives.
- If your PowerPoint presentation has embedded contents such as video or images and/or the presentation exceeds 100MB, please contact the Organ Systems Branch before submitting online. This will help us avoid technical difficulties. More details will be available on the Workshop Web site.

GENERAL

General Information

Workshop Deadlines

Abstract Submission	April 14, 2006
Satellite Meeting Requests	May 30, 2006
Organ Site Breakout Agendas	June 3, 2006
Workshop Registration	June 16, 2006
Hotel Registration	June 16, 2006
PowerPoint Presentation Submission	June 30, 2006

Workshop Registration Information

Registration for the Workshop will be submitted online at <http://sporemeeting.nci.nih.gov>. All information and transactions collected will be safe and secure using SSL technology. This is a Government-sponsored meeting that is open to the public. Your contact information will be printed in Workshop materials. Please do not provide personal contact information during registration.

The deadline for Workshop registration is June 16, 2006.

Incidental Fees

U.S. Government Employee	\$50	
Non-U.S. Government Employee	\$300	(i.e., SPORE Investigator, SPORE Administrator, non-sponsored Patient Advocate and/or guest, and investigators)
Industry Representative	\$300	

Registration Cancellation and Refund Policy

All requests for refunds must be e-mailed to Theresa O'Toole, totoole@md.capconcorp.com, and approved by the OSB.

- Requests for refunds before June 16 will incur a \$50 cancellation fee.
- After June 16 and through June 30, there will be a cancellation fee of \$100.
- After June 30, there will be no refunds.
- No-shows will not be refunded.

GENERAL

General Information

Hotel Information

Workshop Location

Baltimore Marriott Waterfront
700 Aliceanna Street
Baltimore, MD 21202

Phone: 1-410-385-3000
Fax: 1-410-895-1900
Toll-free: 800-228-9290
www.marriott.com/BWIWF

Set on the edge of the Inner Harbor, the four-diamond AAA Baltimore Marriott Waterfront is just steps from the city's best dining, entertainment, and cultural venues.

Arrival Information

Check-in time, 4 p.m.

Check-out time, 12 noon

Video review billing; video check-out; express check-in and check-out

General Information and Rates

Single/Double/Triple/Quad: \$155 may have availability 3 days before and 3 days after the Workshop.

To reserve a room with the special rates listed above, you must contact the Baltimore Marriott Waterfront reservation desk at 410-385-3000 on or before June 16, 2006. Please identify yourself as attending the 14th SPORE Workshop and provide the special group code, "SPOSPOA." All reservations must be accompanied by a first night's room deposit or guaranteed with a major credit card and must be received on or before Friday, June 16, 2006.

Or, for a direct link to the Baltimore Marriott Waterfront reservation site that is preconfigured with the Workshop's rates, please access this url: www.marriott.com/BWIWF.

Parking

Onsite parking fee: \$8 hourly, \$20 daily; valet parking fee: \$30 daily.

Hotel Cancellation Policy

To cancel your hotel reservation, you must contact the Baltimore Marriott Waterfront reservation desk at 410-385-3000 no later than 6 p.m. on the day of your scheduled arrival. You will be charged for one night's stay if your reservation is not cancelled with sufficient notification.

GENERAL

General Information

Airport and Ground Transportation Information

Airports

Three major airports serve Baltimore:

Baltimore Washington International Thurgood Marshall Airport (BWI) in Maryland
<http://www.bwiairport.com>, 1-800-435-9294 or 410-859-7111, TTY: 410-859-7227 (Baltimore area only)

Driving directions: From Baltimore-Washington International Thurgood Marshall Airport: Take Baltimore/Washington Parkway North 8 miles to Pratt Street; turn right. Proceed to President Street; turn right onto President Street. Turn right onto Aliceanna. The hotel is on the right. Hotel direction: 8.0 miles SE.

Estimated taxi fare: \$20 (one way)

Washington Dulles International Airport (IAD) in Northern Virginia
<http://www.mwaa.com/dulles/index.htm>, 703-572-2700

Driving directions: From Washington Dulles International Airport: Take the Dulles Toll Road East to I 495 North. Proceed on I 495 North to I 95 North. Follow I 95 North to I 395 Downtown Baltimore to Pratt Street; turn right. Proceed to President Street; turn right on President Street. Turn right onto Aliceanna. The hotel is on the right. Hotel direction: 45.0 miles N.

Estimated taxi fare: \$100 (one way)

Ronald Reagan Washington National Airport (DCA) in Northern Virginia
<http://www.mwaa.com/national/index.htm>, 703-417-8000

Driving directions: From Ronald Reagan Washington National Airport, Washington, DC: Take George Washington Parkway North to I 495 and proceed North to I 95 North. Follow I 95 North to I 395 to Pratt Street; turn right. Proceed on Pratt Street to President Street; turn right onto President Street. Turn right onto Aliceanna. The hotel is on the right. Hotel direction: 52.0 miles NE.

Estimated taxi fare: \$90 (one way)

Alternative: Take the Metro to Union Station (\$1.75) (www.wmata.com) and then Amtrak (www.amtrak.com) to Baltimore.

Trains and Public Transportation

AMTRAK, <http://www.amtrak.com/servlet/ContentServer?pagename=Amtrak/HomePagetrains>, runs 24 hours per day, 7 days per week. For fares and schedules, call 1-800-872-7245.

Please visit the SPORE Workshop Web site at <http://sporemeeting.nci.nih.gov> for more information about public transportation.

ACKNOWLEDGEMENTS

Meeting Support and Special Acknowledgements

Planning Committee

James Abbruzzese, M.D., Director, Pancreatic SPORE
The University of Texas M.D. Anderson Cancer Center

Kenneth Anderson, M.D., Director, Myeloma SPORE
Dana-Farber/Harvard Cancer Center

Robert Bast, Jr., M.D., Director, Ovarian SPORE
The University of Texas M.D. Anderson Cancer Center

Thomas Burke, M.D., Director, Gynecologic SPORE
The University of Texas M.D. Anderson Cancer Center

Gary Clayman, M.D., Director, Head & Neck SPORE
The University of Texas M.D. Anderson Cancer Center

Deborah Collyar, Co-Leader, Patient Advocate Research Team Program

Colin Dinney, M.D., Director, Genitourinary SPORE
The University of Texas M.D. Anderson Cancer Center

Shelton Earp III, M.D., Director, Breast SPORE
University of North Carolina at Chapel Hill

Joe W. Gray, Ph.D., Director, Breast SPORE
University of California, San Francisco

Meenhard Herlyn, D.V.M., Sc.D., Director, Skin SPORE
The Wistar Institute/University of Pennsylvania

Jean-Pierre Issa, M.D., Director, Leukemia SPORE
The University of Texas M.D. Anderson Cancer Center

Scott Kern, M.D., Director, Gastrointestinal SPORE
Johns Hopkins University

Paula Kim, Patient Advocate, Pancreatic SPORE
The University of Texas M.D. Anderson Cancer Center

Paul Lange, M.D., Director, Prostate SPORE
University of Washington

ACKNOWLEDGEMENTS

Meeting Support and
Special Acknowledgements

Marston Linehan, M.D., Chief, Urologic Oncology Branch, Center for Cancer Research
National Cancer Institute, National Institutes of Health

Christopher Logothetis, M.D., Director, Prostate SPORE
The University of Texas M.D. Anderson Cancer Center

Brian O'Neill, M.D., Director, Brain SPORE
Mayo Clinic, Rochester

Jill Siegfried, Ph.D., Director, Lung SPORE
University of Pittsburgh

Patricia Steeg, Ph.D., Director, Molecular Therapeutics Program, Center for Cancer Research
National Cancer Institute, National Institutes of Health

David Sturges, Patient Advocate, Lung SPORE
University of California, Los Angeles

George Weiner, M.D., Director, Lymphoma SPORE
University of Iowa-Mayo Clinic, Rochester

National Institutes of Health Facilitators

Michael Birrer, M.D., Ph.D.

William Dahut, M.D.

Geraldina Dominguez, Ph.D.

William Figg, Pharm.D.

Jane Fountain, Ph.D.

James Jacobson, Ph.D.

Karen Johnson, M.D., Ph.D., M.P.H.

Gary Kelloff, M.D.

Marston Linehan, M.D.

Tracy Lively, Ph.D.

Alison Martin, M.D.

Suresh Mohla, Ph.D.

Scott Saxman, M.D.

Yasaman Shirazi, Ph.D.

Malcolm Smith, M.D., Ph.D.

Magdalena Thurin, Ph.D.

Ted Trimble, M.D.

Mukesh Verma, Ph.D.

Barbara Vonderhaar, Ph.D.

Paul Wagner, Ph.D.

Linda Weiss, Ph.D.

Roy Wu, M.D., Ph.D.

ACKNOWLEDGEMENTS

Meeting Support and Special Acknowledgements

Organ Systems Branch

Jorge Gomez, M.D., Ph.D., Chief
Teri Brown, Program Coordinator
Sarah Fabian, Program Coordinator
Katherine Sachs, Program Coordinator

Ivan Ding, M.D., Program Director
Andrew Hruszkewycz, M.D., Ph.D.,
Program Director
Peter Ujhazy, M.D., Ph.D., Program Director

Capital Consulting Corporation

CONTACT Contact Information

Capital Consulting Corporation (CCC) is the logistical contractor for the Workshop. CCC's general contact information is as follows:

Capital Consulting Corporation
11821 Parklawn Drive, Suite 100
Rockville, MD 20852-2539
301-468-6004 (Phone)
301-468-0338 (Fax)

14th SPORE Investigators' Workshop
Toll-free number: 866-714-2551
E-mail: 14thSPORE@md.capconcorp.com

For questions about registration, contact:
Theresa O'Toole, ext. 420
totoole@md.capconcorp.com

For questions about meeting logistics, contact:
Ruby Gerald, ext. 422
rgerald@md.capconcorp.com

For questions about supported participants, contact:
Jennifer Kostiuk, ext. 424
jkostiuk@md.capconcorp.com

For questions about program content, contact:
Organ Systems Branch
National Cancer Institute
6116 Executive Boulevard, Suite 7008
Rockville, MD 20852
301-496-8528 (Phone)
301-402-5319 (Fax)
nciosbspore-r@mail.nih.gov



NATIONAL[®]
CANCER
INSTITUTE